Tirzepatide is a laboratory-developed compound designed to study dual incretin activity in controlled research settings. As a GLP-1/GIP peptide, it supports consistent interactions within metabolic and endocrine systems during experimental evaluation. Its design allows researchers to observe how coordinated signaling processes respond to a single peptide model.
Tirzepatide is being examined for its role in metabolic regulation and intercellular communication. It helps researchers explore how peptide-driven signaling may influence glucose-related activity, energy balance, and hormone-associated responses. Its application in laboratory settings provides insight into how interconnected biological systems adapt under controlled conditions.
Tirzepatide (100mg) Key Features & Specs
- Subcategory: Weight Loss & Metabolic Peptides
- Strength: 100mg
- CAS: 2023788-19-2
- Chemical Formula: C₂₂₅H₃₄₈N₄₈O₆₈
- Molecular Weight: 4813.48 g/mol
- Peptide Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys(C20-linker)-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
- Synonyms: P1206, LY3298176, tirzepatida, tirzepatidum, OYN3CCI6QE
For laboratory research use only.
Tirzepatide (100mg) Research Uses
Tirzepatide is studied to understand how metabolic systems coordinate under controlled conditions. It has been examined for its potential to influence cellular responses to nutrient signals, particularly in environments evaluating glucose handling and energy distribution. These studies focus on how different biological systems communicate and adapt when exposed to peptide-based compounds.
Ongoing research also investigates how the Tirzepatide peptide interacts with regulatory mechanisms linked to appetite signaling and metabolic balance. Researchers use structured models to observe how these processes function together, providing a clearer understanding of how multi-pathway peptides behave across interconnected systems.
Tirzepatide (100mg) Insights & Observed Findings
Tirzepatide research includes data from in vitro and preclinical models, with experimental conditions varying by study focus. Researchers adjust concentrations and environmental conditions to observe specific biological responses, enabling a careful evaluation of the peptide's performance.
Studies have shown consistent patterns in metabolic activity and cellular behavior. Observations focus on how signaling responses are initiated and maintained over time in experimental systems. These findings remain exploratory and support further investigation rather than clinical conclusions.
Tirzepatide (100mg) Handling & Storage
- Store Tirzepatide (100 mg) at –20°C in a controlled laboratory setting, protected from light, heat, and moisture to maintain integrity.
- After reconstitution, store the solution refrigerated.
- Handle the reconstituted solution carefully to maintain consistency in experimental conditions.
- Avoid repeated freeze-thaw cycles.
Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.
References
- National Center for Biotechnology Information. PubChem Compound Summary for CID 156588324, Tirzepatide. https://pubchem.ncbi.nlm.nih.gov/compound/156588324
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. Published 2020 Sep 3. doi:10.1172/jci.insight.140532
- Sun B, Willard FS, Feng D, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022;119(13):e2116506119. doi:10.1073/pnas.2116506119
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009
- Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022;27(13):4315. Published 2022 Jul 5. doi:10.3390/molecules27134315